Press Releases

New York, June 2022: According to a new research study by Global Insight Services (GIS), the companion animal pharmaceutical market is expected to grow rapidly over the next 10 years to reach a value of more than the US $26.8 billion by 2031.

The rising adoption of pet animals due to growing urbanization and an increase in the number of nuclear families is among the primary market growth factors. A growing focus on animal health along with surging demand for pet insurance, especially in developed countries will augment the market expansion. The consistent rise in the number of diseases affecting animals is, in turn, generating demand for companion animal drugs. Additionally, industrial growth is attributable to the increasing incidence of zoonotic and food-borne diseases across the globe.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10260/

Global Companion Animal Pharmaceutical Market: Key Drivers

The key factors such as the growing prevalence of zoonotic diseases is boosting the market growth during the forecast period. Some pathogens, such as zoonotic, can be transmitted from animals to humans. Examples of zoonotic diseases include rabies, salmonellosis, plague, brucellosis, and Lyme disease. Animals also share our susceptibility to certain diseases and environmental hazards and can serve as an early warning for potential human infections. Over the past two decades, the incidence of zoonotic diseases has increased across the globe, primarily as a result of the increased pet population. According to the International Livestock Research Institute (ILRI), 13 zoonoses cause 2.4 billion cases of human diseases and 2.2 million deaths every year. Toxoplasmosis—which is transmitted via cat feces—is quite common, with 10–20% of the UK population and 22% of the US population expected to carry the parasite as cysts. Cats with chronic bacteremia are primarily infected through saliva, and there is a high risk of transmittance from young adult cats. Although cats are asymptomatic carriers, weaker individuals can develop generalized infections. Many of the emerging and re-emerging infectious disease threats are vector-borne diseases transferred to animals and humans from arthropods.

Report Findings

The dermatologic segment is likely to dominate the market during the forecast period

The increasing prevalence of arthritis coupled with the rising need for advanced orthopedic drugs, and the growing pet population are some key factors boosting the market growth.

The dog segment is anticipated to dominate the market during the forecast period

The key factors such as the increasing dog’s population coupled with a rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe are boosting the market growth.

The veterinary hospital segment is estimated to dominate the market during the forecast period

The key factors such as the animal parasiticides and antibiotics in hospital settings coupled with increasing incidence of infectious diseases, a growing number of veterinary hospitals, growing ownership of companion animals and increasing veterinary expenditure, and growing awareness about animal health in developing countries are some factors driving the growth of the segment.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10260/

Competitive Landscape

The key factors in the global companion pharmaceutical market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Global Companion Animal Pharmaceuticals Market Segmentation

By Indication

• Infectious Diseases
• Dermatologic Diseases
• Pain
• Orthopedic Diseases
• Behavioral Diseases
• Others

By Animal Type

• Dogs
• Cats
• Horses
• Others

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Retail Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10260/

Global Companion Animal Pharmaceutical Market: Recent Developments

• February 2020, Vetoquinol acquired Canadian rights for the Profender product family from Elanco Animal Health. The acquisition is poised to impact the company’s revenue and offer business development opportunities in untapped economies.
• September 2020, Virbac acquired a range of Tilapia vaccines from Ictyogroup to distribute and market them across the globe.
• August 2020, Elanco Animal Health Incorporated announced that it has acquired Bayer Animal Health. The transaction was valued at USD 6.89 billion. This development helped the economy to expand itself in the durable animal health industry.
• June 2020, Merck invested USD 100 million in facility expansion and enhancement efforts in its US manufacturing site in De Soto, Kansas. This site also comprises an additional expansion of the vaccine production facility, so enhancing its manufacturing and capabilities.
• February 2020, Zoetis received FDA approval for Simparica Trio.
• February 2019, Zoetis launched Eradia, an antibiotic for dogs, in Europe.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the companion diagnostics market is expected to grow rapidly over the next 10 years to reach a value of more than the US $18.0 billion by 2031.

Companion diagnostics is a medical device used along with therapeutic drugs to analyze the effect & applicability of drugs on a specific human body. Companion diagnostics are developed along with drugs for selecting or excluding groups of patients based on the characteristics of which they respond to the therapy. This device helps the healthcare professional to analyze whether a particular treatment is beneficial to the patient.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10261/

Global Companion Diagnostics Market: Key Drivers

The key factor such as the growing requirement for targeted medicine is boosting the growth of the market. With advances in genetic sequencing and genomics, it is now extensively believed that drugs can show varying outcomes in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering ‘the right drug, at the right time, at the right dose, for the right person. Pharmaceutical and biopharmaceutical companies are regularly attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further boosted the growth of the companion diagnostics market.

Similarly, the increasing demand for next-generation sequencing is also refueling the market during the forecast period. NGS-based companion diagnostic target to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of various types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. Owing to that, major market players are focusing on developing companion diagnostic products based on NGS.

Report Findings

The assay, kits & reagents accounted for the largest share of the companion diagnostics market in 2021

The factors such as the availability of a wide range of products coupled with the increasing use of assays and kits in different therapeutic areas are boosting the growth of the market.

The PCR segment is likely to dominate the market during the forecast period

Ease of use coupled with the widespread availability of PCR kits & reagents in companion diagnostic testing and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes are some factors boosting the market growth.

The cancer segment is likely to dominate the market during the forecast period

Factors such as the growing role of companion diagnostics in the personalized medicine treatment for cancer coupled with the increasing utility of biomarkers in the diagnosis of cancer are boosting the market growth.

The pharmaceutical & biopharmaceutical companies segment is likely to dominate the market during the forecast period

The key factors such as the growing use of companion diagnostics owing to their increasing prominence in drug development coupled with the increasing importance of companion diagnostic biomarkers are boosting the market growth.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10261/

Competitive Landscape

The key players of the companion diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Global Companion Diagnostics Market Segmentation

By Products & Services

• Assays, Kits & Reagents
• Software & Service

By Technology

• Polymerase Chain Reaction
• Next-Generation Sequencing
• In Situ Hybridization
• Immunohistochemistry
• Other

By Indication

• Cancer
• Neurological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Others

By End User

• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10261/

Global Companion Diagnostics Market: Recent Developments

• May 2021, QIAGEN N.V. (Germany) expanded the therascreen KRAS Kit.
• May 2020, Medical and Biological Laboratories Co. Ltd., announced that it has launched an in vitro diagnostic kit for the genetic disease Spinal Muscular Atrophy. The MEBCDX AAV9 test kits, was licensed from Quest Diagnostics.
• May 2019, QIAGEN N.V. launched the therascreen PIK3CA RGQ PCR kit in PIQRAY therapy in the U.S. to enhance its product portfolio in the Companion Diagnostics Market.
• April 2019, Roche Diagnostics acquired TIB Molbiol Group. This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the compression therapy market is expected to grow rapidly over the next 10 years to reach a value of more than the US $6.8 billion by 2031.

Compression therapy uses controlled pressure on the lower extremities to increase blood flow and efficiency of the lymphatic and venous system. It is the most established and the most important method of treatment for venous and lymphatic diseases. According to an article published by the National Center for Biotechnology Information (NCBI) in 2018, lymphedema is a pandemic and affects approximately 250 million patients across the globe. The increase in the prevalence of vein disorders such as venous leg ulcer, lymphedema, deep vein thrombosis, etc., the increasing geriatric population, and the rise in the adoption of pressure therapies for the treatment of these vein disorders are the key factors likely to drive the compression therapy market growth during the projection period.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10262/

Global Compression Therapy Market: Key Drivers

The presence of a large target patient population is boosting the market growth of the global compression therapy market. The target population for compression therapy products includes patients suffering from lifestyle-related diseases and vascular diseases, like obesity, diabetes, lymphedema, DVT, and varicose veins. The rising geriatric population across the globe is the primary factor supporting market growth as geriatric individuals are more susceptible to various health conditions. These factors are driving the demand and adoption of various treatment procedures, including compression therapy, among patients. Moreover, compression therapy products are increasingly being preferred as the first line of treatment for major target indications and for post-surgery rehabilitation.

Report Findings

The compression garments segment is anticipated to dominate the market during the forecast period

The factors such as the use of compression garments in a wide range of indications, like varicose veins, edema, DVT, and lymphedema, as well as in the management of several chronic conditions are propelling the growth of the market.

Static compression therapy is likely to dominate the market during the forecast period

The key factors such as the presence of a large target population coupled with increasing incidences of sports injuries and accidents are boosting the growth of the market.

The lymphedema treatment segment is likely to boost the growth of the market

The key factors such as the rising incidence of lymphedema and the high presence of compression therapy products for the treatment and management of lymphedema among end user is boosting the market growth.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10262/

Competitive Landscape

The key players in the global compression therapy market are DJO Global, Inc. (US), BSN medical (US), medi GmbH & Co. KG (Germany), Tactile Medical (US), SIGVARIS (Switzerland), Paul Hartmann AG (Germany), Sanyleg S.r.l. (Italy), 3M (US), ConvaTec Inc. (US), ArjoHuntleigh (Sweden), Julius Zorn GmbH (Germany), Bio Compression Systems, Inc. (US), Cardinal Health, Inc. (US), and Smith & Nephew plc (UK).

Global Compression Therapy Market Segmentation

By Product

• Compression Garments
• Compression Braces
• Compression Pumps

By Technique

• Static Compression Therapy
• Dynamic Compression Therapy

By Application

• Varicose Vein Treatment
• Deep Vein Thrombosis Treatment
• Lymphedema Treatment
• Leg Ulcer Treatment
• Others

By Distribution Channel

• Pharmacies & Retailers
• Hospitals & Clinics
• E-Commerce Platforms

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10262/

Global Compression Therapy Market: Recent Developments

• May 2021, FDA has given clearance to Koya Medical’s compression therapy system for lower extremities.
• April 2021, Essity acquired by ABIGO Medical. The acquisition added to the company’s wound care product portfolio.
• April 2021, DJO acquired MedShape, Inc. This acquisition will strengthen DJO’s portfolio of fracture fixation, joint fusion, and soft tissue injury repair products, which utilize biomaterial technologies designed to improve patient outcomes.
• February 2021, De Royal signed a USD 1.2 million agreement with Tyndall and RCSI SWaT researchers. The primary objective of this partnership was to transform compression wound therapy.
• November 2020, Theragun. Inc. had acquired RP Sports, one of the leaders in clinical pneumatic compression. Theragun, Inc. has acquired RP Sport’s groundbreaking clinical technology product line, Recovery Pump.
• July 2020, AIROS Medical Inc., announced the launch of its updated compression therapy products. The company’s new AIROS 6 Sequential Compression Therapy device and Arm Plus garments had been approved by the FDA for the first time in three years.
• June 2020, Medi GmbH & Co. KG launched mediven cosy 450, which added to its flat-knit compression portfolio.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the continuous renal replacement therapy market is expected to grow rapidly over the next 10 years to reach a value of more than the US $2.6 billion by 2031.

Continuous renal replacement therapy (CRRT) is a popular choice of therapy usually used for renal support in critically ill patients with acute kidney injury (AKI), primarily in hemodynamically unstable patients. It comprises the solute removal from the blood through the process of hemodialysis or hemofiltration or a combination of both methods. The CRRT therapy is generally carried out for about 24 hours in an ICU, making it altered from other kinds of conventional renal replacement therapies such as intermittent hemodialysis (IHD) which lasts for about 4 to 6 hours or even less.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10263/

Global Continuous Renal Replacement Therapy Market: Key Drivers

The increase in the prevalence of incidence of acute kidney injury is propelling the growth of the market during the forecast period. The increasing global incidence of AKI/AKF is, therefore, expected to increase the demand for CRRT. According to the International Society of Nephrology (INR), an anticipated 13.3 million cases of AKI are registered annually across the globe. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the geriatric population globally, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is anticipated to propel the growth of the CRRT market at a significant rate during the forecast period.

Similarly, emerging markets in APAC and RoW are also offering various growth opportunities during the forecast period. Emerging markets like China, India, Brazil, and Mexico are anticipated to offer significant growth opportunities for players in the CRRT market. According to an article published by the Journal of Clinical and Diagnostic Research (JCDR) 2018, in a prospective observational study conducted on 100 critically ill patients. In India, AKI was observed in 17.3 cases/1,000 persons. To leverage the significant growth opportunities in emerging countries, players are progressively focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia Pacific region are more adaptive and business-friendly owing to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage CRRT product manufacturers to focus on the emerging markets.

Report Findings

The dialysates and replacement fluid segment is likely to dominate the market during the forecast period

The key factors such as benefits of convection and diffusion for the removal of solutes, which is another major factor boosting the market growth during the forecast period.

The CVVH segment is likely to dominate the market during the forecast period

The CVVHDF is likely to dominate the market during the forecast period. The high growth rate of the CVVHDF segment is attributed to its flexibility as compared to other CRRT modalities. The CVVHDF modality also combines the benefits of convection and diffusion for the removal of the solutes, which is another factor supporting the growth of the segment.

The adult segment is likely to dominate the market during the forecast period

The increasing demand for invisible braces among adults owing to the large adult population base with AKI, the increase in the hospitalization among the adult population, and the large availability of CRPT systems and disposables of adults undergoing CRRT procedures.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10263/

Competitive Landscape

The key players studied in the continuous renal replacement therapy market are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China), Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China).

Global Continuous Renal Replacement Therapy Market Segmentation

By Product

• Dialysates and replacement fluids
• Disposables
• Hemofilters
• Bloodline sets & tubes
• Others

By Modality

• Continuous venovenous hemofiltration (CVVH)
• Continuous venovenous hemodiafiltration (CVVHDF)
• Continuous venovenous hemodialysis (CVVHD)
• Slow continuous ultrafiltration (SCUF)

By Age Group

• Adults
• Pediatrics/Neonates

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10263/

Global Continuous Renal Replacement Therapy Market: Recent Developments

• February 2021, DaVita accomplished its first position by including a secure telehealth platform, DaVita Care Connect, into its home dialysis program.
• December 2020, Medtronic announced the launch of the Carpediem System, the first and only pediatric and neonatal acute dialysis designed to treat patients weighing 2.5-10Kg requiring renal replacement therapy.
• July 2019, Baxter Internatinal Inc. introduced the Pris Max CRRT system in the US.
• January 2019, Fresenius Medical Care AG & KGaA announced the launch of the 4008A dialysis machines in India.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the brain monitoring market is expected to grow rapidly over the next 10 years to reach a value of more than the US $7.2 billion by 2031.

Brain monitoring helps clinicians in monitoring the condition of the brain under the influence of anesthesia through bilateral data acquisition and processing of the EEG signals. Brain monitoring devices are used to monitor and diagnose neurological conditions by exploring the structure and function of the brain. This process involves the use of several brain monitoring devices. At present, there is an increase in the demand for electroencephalography devices among healthcare providers.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10247/

Global Brain Monitoring Market: Key Drivers

The major factor boosting the growth of the market is the increasing incidence and prevalence of neurological disorders. The global incidence and prevalence of neurological disorders, like dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuro infections, stroke, and cerebral palsy, have increased significantly during the last few years. Brain disorders, which comprise a combination of developmental, psychiatric, and neurodegenerative diseases, are a growing cause of morbidity worldwide. This can mainly be attributed to the growing geriatric population (by 2050, more than 20% of the global population is expected to be aged over 65 years). The American Medical Association (AMA) anticipates that at least 60% of individuals aged 65 years and above will be living with more than one chronic condition by 2030.

The rising incidences of these neurological disorders have made it extremely important to monitor brain and neurological function. Many neurological disorders and conditions are progressive, and their risk increases with age. Adding to that, the prevalence of other diseases and conditions, such as sickle-cell diseases and cardiac disorders, is also increasing. Cardiac procedures may sometimes affect the normal functioning of the brain, which is another factor driving the demand for brain monitoring devices.

Report Findings

The electroencephalography devices segment is likely to dominate the market during the forecast period

The surge in demand for the diagnosis of critical disorders such as epilepsy has further influenced companies to focus on the development of brain monitoring EEG devices.

The non-invasive segment accounted for the fastest growth during the forecast period

The key factors such as rise in incidences of traumatic brain injuries coupled with a high acceptance rate of minimally invasive devices, and a low risk of mortality. This increases the demand for these products which propels the market growth.

The epilepsy segment is anticipated to dominate the market during the forecast period

The key factors such as the increasing geriatric population and the rise in the prevalence of neurological disorders are boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10247/

Competitive Landscape

The global brain monitoring market report includes players such as Advanced Brain Monitoring, Inc., CAS Medical Systems, Inc, Compumedics Ltd, General Electric Company (GE Healthcare), Koninklijke Philips N.V. (Philips Healthcare), Medtronic Plc., Natus Medical Incorporated, Neural Analytics, Inc., Siemens AG, Cadwell Laboratories, Neurosoft Limited, Elekta A.B., InfraSacn, Inc. and BrainScope Company, Inc. among others.

Global Brain Monitoring Market Segments

By Product Type

• Electroencephalography (EEG) Devices
• Magnetoencephalography (MEG) Devices
• Transcranial Doppler (TCD) Devices
• Intracranial Pressure (ICP) Monitors
• Cerebral Oximeters
• Magnetic Resonance Imaging (MRI) Devices
• Computerized Tomography (CT) Devices
• Positron Emission Tomography (PET) Devices
• Sleep Monitoring Devices
• Electromyography (EMG) Devices
• Accessories

By Procedure

• Invasive
• Non-invasive

By Application

• Epilepsy
• Dementia
• Parkinson’s Disease
• Huntington’s Disease
• Headache Disorders
• Stroke
• Traumatic Brain Injuries
• Sleep Disorders
• Other Diseases

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10247/

Global Brain Monitoring Market: Recent Developments

• September 2021, NeuroWave Systems Inc. announced the FDA clearance of its Neuro SENSE NS-901 Monitor- a new generation brain function monitor for assessing the adequacy of anesthesia and sedation in clinical settings.
• November 2021, Brain Scientific received FDA clearance for Next-Gen Neuro Cap EEG Headset, and advanced electroencephalogram electrodes array used to obtain rapid EEG’s in routine clinical and research settings where the recording of STAT EEG’s is desired.
• February 2020, Compumedics announced milestone US FDA approval for the Orion Life Span MEG.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the closed system transfer devices market is expected to grow rapidly over the next 10 years to reach a value of more than the US $4834.1 million by 2031.

A closed system transfer device or “CSTD” is a drug transfer device, which mechanically restricts the transfer of environmental contamination in the medical system and the escape of hazardous drug or vapor concentrations outside the system. Open versus closed systems are commonly applied in medical devices to maintain the sterility of a fluid pathway. CSTDs work by preventing- uncontrolled inflow and outflow of contaminants and drugs, preserving the quality of the solution to be infused into a patient. These devices ensure the safety of healthcare workers during the usage of hazardous drugs or chemicals. Closed system transfer device designs and models have changed at a rapid rate in recent years, resulting in the development of a number of independent testing methodologies to assess closed system transfer device performance. Currently, manufacturers in the closed system transfer devices market are focusing more on adhering to performance requirements, which largely focus on patient safety and sterile practices.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10257/

Global Closed System Transfer Devices Market: Key Drivers

The key factors such as rising use of CSTDs to combat the harmful effect of cytotoxic and antineoplastic drugs. Antineoplastic drugs are widely used in the treatment of cancer and are considered hazardous drugs. Healthcare workers involved in the preparation, transport, distribution, administration (pre and post-administration), and disposal of these drugs are at extremely high risk. The National Institute for Occupational Safety and Health (NIOSH) recommends the use of CSTDs to eliminate the harmful effects caused by exposure to hazardous substances that escape out of the system during drug preparation and administration. CSTDs act as a barrier and prevents the entry of contaminants prevent the transfer of contaminants from the atmosphere to a sterile environment. Due to these advantages, CSTDs are increasingly being used in healthcare facilities to combat the harmful effects of hazardous drugs.

Chemotherapy, a widely adopted cancer treatment, uses one or more antineoplastic drugs, which destroy abnormal cells in patients. The use of closed system transfer devices (CSTDs) in conjunction with other safety precautions such as gloves, gowns, masks, and vented preparation hoods is an effective way to increase safety when preparing, transporting, administering, and disposing of hazardous drugs. With the increasing incidence of cancer and increasing adoption of chemotherapy treatments, the demand for CSTDs is expected to increase in the upcoming years.

Report Findings

Color to color alignment system is likely to dominate the market during the forecast period

Owing to its unique structure that prevents leaks, spills, or the escape of vapors and aerosols. These devices equalize the pressure within the system when fluids are withdrawn or injected into vials. Additionally, the low cost of this system, along with its advantages, increased its adoption among pharmacists, oncologists, and nurses.

The membrane to membrane system is anticipated to dominate the market during the forecast period

The key factors such as ease of operation and lower risk of contamination associated with double membrane containment systems are boosting the market growth.

The vial access devices segment is estimated to dominate the market during the forecast period

The key factors such as rising adoption of CSTDs products and vial access device by oncology nurses to transfer hazardous drugs from packaged vials to the infusion bag or the patient.

The hospitals & clinics segment is likely to dominate the market during the forecast period

The large share and high growth of this segment are primarily owing to the strong financial capabilities of hospitals for purchasing high-priced CSTDs, the large cancer patient pool, and the need to comply with regulatory guidelines.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10257/

Competitive Landscape

The key players in the closed system transfer devices market are B. Braun Holding GmbH & Co. KG, Baxter International, Becton, Dickinson and Company, Caragen Ltd, Corvida Medical, Equashield, FIMI Opportunity Funds (Simplivia Healthcare), ICU Medical, JCB Co Ltd. (JMS Co Ltd.), Yukon Medical.

Global Closed System Transfer Devices Market Segmentation

By Closing Mechanism

• Push to Lock System
• Click to Lock System
• Luer Lock System
• Color to Color Alignment System

By Type

• Membrane to Membrane Systems
• Needleless Systems

By Component

• Vial Access Devices
• Syringe Safety Devices
• Bag/Line Access Devices
• Accessories

By End User

• Hospitals & Clinics
• Oncology Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10257/

Global Closed System Transfer Devices Market: Recent Developments

• January 2021, Simplivia Healthcare acquired 70% of Novame d, a diagnostic company that develops and manufactures a range of diagnostic kits to meet evolving trends of home care.
• May 2021, BD expanded its drug delivery devices segment by establishing a high-tech manufacturing facility in Zaragoza, Spain.
• May 2021, Yukon Medical received US FDA clearance for Arisure closed system transfer device under the ONB product classification.
• November 2020, Equashield LLC partnered with Syntronic Hospitalar to introduce Equashield’s products in Brazil.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cold pain therapy market is expected to grow rapidly over the next 10 years to reach a value of more than the US $3.2 billion by 2031.

Cold pain therapy includes the usage of cold materials to relieve pain. Cryotherapy is generally used as an essential injury management skill. Ice packs are applied to inflammations and injuries to help reduce pain and swelling. Studies suggest that cold compression slows blood flow to the injury, thereby reducing pain, inflammation, and muscle spasm. Ice packs are effective, inexpensive, and drugless methods to relieve pain from sprains, strains, bruises, tendinitis, and swelling caused due to trauma to superficial tissues. Cold packs, used on inflammations act as a primary analgesic to relieve pain. Cold pain therapy is primarily used on fresh injuries such as ligament sprains, muscle sprains, and severe bruises. This therapy is used for chronic overuse or tissue fatigue injuries such as carpal tunnel syndrome, tennis elbow, supraspinatus tendinitis, iliotibial band syndrome, patellofemoral pain syndrome, and plantar fasciitis.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10258/

Global Cold Pain Therapy Market: Key Drivers

The key factor boosting the market growth is increasing the number of hip and knee surgeries. There has been observed that aging-related changes in the musculoskeletal system increase the propensity to osteoarthritis (OA), and the severity of the disease is closely related to other OA risk factors such as joint injury, obesity, genetics, and anatomical factors that affect joint mechanics. OA is not an inevitable consequence of growing old, although older age is the greatest risk factor for OA. The market demand for surgical treatment, including joint replacement surgery (hip and knee replacement), is expected to increase significantly, owing to the rapidly increasing aging population across the globe.

Similarly, the increasing adoption of analgesic patches is also refueling the market growth. Analgesic patches feature a transdermal drug delivery system, which is a non-invasive mode of medication delivery through the skin. Patches deliver an analgesic drug at a fixed rate across the dermis, while placed on the skin. The use of analgesic patches through transdermal drug delivery systems offers certain advantages over oral medications.

Report Findings

The OTC product segment is likely to dominate the market during the forecast period

The easy accessibility of OTC products in retail and online pharmacies is boosting the growth of the OTC segment in the global cold pain therapy market.

The musculoskeletal disorders segment is anticipated to dominate the market during the forecast period

Factors such as immediate pain relief provided by cold pain therapy products are boosting the market growth during the forecast period.

The retail pharmacies segment is likely to dominate the market during the forecast period

The easy availability of all the essential cold pain therapy products in retail pharmacies is boosting the growth of this market during the forecast period.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10258/

Competitive Landscape

The key players in the global cold pain therapy market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).

Global Cold Pain Therapy Market Segmentation

By Product

• OTC Products
• Prescription Products

By Application

• Musculoskeletal Disorders
• Post-operative Therapy
• Sports Injuries
• Post-trauma Therapy

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• E-Pharmacies

By End User

• Hospitals & Clinics
• Oncology Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10258/

Global Cold Pain Therapy Market: Recent Developments

• June 2021, Hisamitsu Pharmaceutical Co., Inc. launched Air Salonpas Z, an analgesic and anti-inflammatory spray for muscle pain, bruises, and sprains, among other conditions.
• November 2020, Beiersdorf AG invested USD 72.9 million (EUR 60 Million) in Hamburg to develop technological centers for strengthening its R&D unit.
• September 2019, Rohto Pharmaceutical announced the launch of an advanced technology research laboratory at the Hong Kong Science Park in New Territory, Hong Kong.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cold plasma market is expected to grow rapidly over the next 10 years to reach a value of more than the US $5.7 billion by 2031.

Cold plasma, also referred to as non-equilibrium plasma or non-thermal plasma is a classification of plasma, and is considered the fourth state of matter. It has numerous applications in bioengineering, medicine, and therapeutics. Cold plasma is used for sterilization of biomedical surfaces, treatment of living biological tissues, and surface modification of biomedical devices and materials, owing to its antimicrobial & bactericidal properties.

The global cold plasma market is driven by less requirement of water for the process reducing the wastewater treatment cost; medical applications, such as enhancement of tissue repair, control of bleeding, destruction of cancer cells; and its application in packaging industries. Still, the huge capital incurred for implementing cold plasma technology is a key hindrance for the market. On the other hand, the growing need for medical research for developing treatment of lung, bladder, skin, and breast cancer offer lucrative opportunities for market growth.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10259/

Global Cold Plasma Market: Key Drivers

The key factors such as the benefits of cold plasma technology are likely to boost the growth of the cold plasma market. Cold plasma technology has diverse applications in several industries. This processing method possesses many advantages, like low water and energy consumption, minimal fiber damage, reduced flammability, low chemical consumption, improved wettability, low cost, and a worker-friendly nature. Also, cold plasma technologies do not require onsite storage of supply chemicals or large volumes of processing water, either for implementation or in post-treatment rinsing. Their advantages, as compared to the currently used alternatives in application industries, have served to boost the adoption of cold plasma techniques.

Similarly, the application of cold plasma in infection prevention and prolonging the life of PPE is also refueling the growth of the market. Cold plasma may be used in the prevention of infectious diseases and nosocomial infections as it kills highly stable multi-resistant microbes. In the COVID-19 pandemic, protective clothing and sterile textiles are in short supply. Treatment with cold plasma or ozone-generating plasma can prolong the use of clothing. It can also help in the hydrophilization process in the textile industry for gloves, PPE kits, and masks to reduce microorganisms. Plasma treat, one of the leading players in the cold plasma market, has developed a prototype cleaning station that provides solutions for disinfecting protective clothing.

Report Findings

The medical industry segment is likely to dominate the market during the forecast period

The advantages of cold plasma treatment coupled with minimal side-effects are propelling the market growth of the segment.

Low pressure plasma segment is likely to dominate the market during the projection period

The key factors such as bacterial activity coupled with minimal surface ablation is boosting the market growth.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10259/

Competitive Landscape

The key players in the global cold plasma market are Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries (US), Acxys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), Terraplasma GmbH (Germany), Molecular Plasma Group (Germany), CINOGY GmbH (Germany), Advanced Plasma Solutions (US), UNIQAIR Technologies (US), PlasmaLeap Technologies (Australia), US Medical Innovations (US), and COMET Plasma Control Technologies (US).

Global Cold Plasma Market Segmentation

By Industry

• Polymer & Plastic Industry
• Textile Industry
• Electronics & Semiconductor Industry
• Food & Agriculture Industry
• Medical Industry

By Regime

• Atmospheric Cold Plasma
• Low-Pressure Cold Plasma

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10259/

Global Cold Plasma Market: Recent Developments

• April 2020, Relyon plasma GmbH launched atmospheric plasma system, piezobrush PZ3.
• February 2020, Hennikar plasma signed a partnership with Irida, this helped the company to strengthen its geographic presence in Spain
• March 2019, Nordson Corporation launched Flex TRAK-SHS automated plasma treatment system. The FlexTRAK-SHS system’s advanced automation enables simultaneous strip buffering and plasma processing for higher chamber utilization normally despite being fully submerged for long periods, and the outer case breached.
• February 2019, P2i launched Drunkable, a system-level waterproofing solution that enables a smartphone to operate normally despite being fully submerged for long periods, and the outer case breached.
• November 2019, Europlasma launched a nanocoating product Plasmaguard.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the breath analyzers market is expected to grow rapidly over the next 10 years to reach a value of more than the US $2594.2 million by 2031.

The Breath Analyzer is a device used to track the Blood Alcohol Content (BAC) in an individual, through a breath sample. The test performed depends upon the relationship between alcohol in the blood or in the breath flowing through the lungs. The rising trend of extreme alcohol consumption resulting in road accidents; has raised the usage of breathalyzer devices. Encouraging government initiatives are also boosting the market growth. Breathalyzer devices are also gaining importance owing to the increasing demand at the workplace for effective BAC (blood alcohol content) levels and their non-invasive nature which is increasing the demand for breath analyzer devices. It is a primary tool for monitoring drugs, alcohol, tuberculosis, asthma, and other diseases hence; it is anticipated that the demand for this system should constantly rise.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10250/

Global Breath Analyzers Market: Key Drivers

The key factors boosting the growth of the market are rising alcohol abuse and drug abuse. In 2018, about 10,511 people in the US died because of drunk driving. Excessive alcohol consumption leads to a high risk of developing more than 200 diseases, comprising liver cirrhosis and some cancers. In the US almost 30 people die every day owing to driving under the influence (DUI). Additionally, high blood alcohol content was observed in~20% of fatally injured drivers in accidents in developed countries. The growing number of road accidents caused by drunk driving and drug abuse has increased the demand for breath analyzers, as these devices assist in monitoring the presence of different compounds and measuring the blood alcohol content in a breath sample.

Similarly, technological advancements are also boosting the growth of the market. The breath analyzers market is technology-driven and is projected to grow at a significant rate in the upcoming years. Due to the lucrative potential of the market, a number of players are focusing on developing novel technologies and are continuously introducing accurate and easy-to-use breath analyzers. For instance, in August 2019, Y Combinator, an investment company, invested in SannTek Labs to work on a new kind of breathalyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person has consumed in the past 3 to 4 hours.

Report Findings

The fuel cells segment is likely to dominate the market during the forecast period

Fuel cell breath analyzers offer an extremely high level of accuracy, sensitivity, and reliability. They are specifically tuned to detect alcohol and do not require multiple sensors. These analyzers are considered the gold standard of handheld alcohol testers for both personal and professional use.

The alcohol detection segment is likely to dominate the market during the forecast period

The key factors such as stringent government regulations for driving under influence (DUI) is boosting the growth of the market.

The law enforcement agencies segment accounted for the largest market share in 2021

The growth of this segment is primarily drivenby stringentsafety laws against DUI and the rising scale of screening and evidential testing are driving the adoption of breath analyzers in law enforcement.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10250/

Competitive Landscape

The global breath analyzer market report comprises players such as Drägerwerk AG & Co. KGaA (Germany), MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany), Lion Laboratories Ltd. (UK), Pas Systems International (US), Guth Laboratories, Inc (US), Alcolizer Technology (Australia), Alcopro, Inc (US), Andatech Private Ltd (Australia), Alere (US), C4 development (China), Advanced Safety Devices (US), and Bedfont Scientific Limited (UK).

Global Breath Analyzers Market Segmentation

By Technology

• Fuel Cell
• Semiconductor Oxide Sensor
• Others

By Application

• Alcohol Detection
• Drug Abuse Detection
• Medical Application

By End User

• Law Enforcement Agencies
• Enterprises
• Individuals

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10250/

Global Breath Analyzers Market: Recent Developments

• July 2020, Lifeloc Technologies launched LT7 and LX0 breath analyzers. These are US DOT/NHTSA approved breath alcohol testers for law enforcement and workplace markets designed to be user-friendly.
• August 2019, Y Combinator, an investment company, invested in Sann Tek Labs to work on a new kind of breath analyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person consumed in the past 3 to 4 hours.
• August 2019, Abbott and Intoximeters signed an agreement for intoximeters to market Abbott’s So Toxa Mobile Test System along with Intoximeter’s Alco-Sensor brand breath alcohol-testing products.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cardiac marker testing market is expected to grow rapidly over the next 10 years to reach a value of more than the US $10.5 billion by 2031.

Cardiac markers are utilized in the treatment and risk stratification of patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers. These biomarkers can be helpful to detect a variety of heart disorders, comprising acute coronary syndrome, cardiac ischemia, and conditions involving obstructed blood flow to the heart. Physicians perform several cardiac marker tests over several hours to keep track of the blood sugar increase and determine the severity of a heart attack.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10254/

Global Cardiac Marker Testing Market: Key Drivers

The key factor boosting the growth of the market is the growing incidence of cardiovascular diseases. The prevalence of lifestyle diseases such as hypertension, obesity, dyslipidemia, and diabetes, which are major risk factors for CVD, is also on the rise. In 2016, more than 1.9 billion adults globally were overweight; of these, over 600 million people were obese. It is anticipated that ~41% of the world’s population will be overweight or obese by 2030. The association between obesity and the risk of coronary heart disease was published by investigators (Bogers RP, Bemelmans WJ, Hogeveen RT, et al.) by a meta-analysis of 21 long-term studies conducted by them with more than 300,000 participants. It was witnessed that participants who were overweight had a 32% higher risk of developing coronary artery disease (CAD), and those who were obese had an 81% higher risk as compared with participants who were a normal weight.

Report Findings

The reagents and kits segment is likely to dominate the market during the forecast period

The growing number of cardiac marker testing procedure, accessibility to a wide range of cardiac biomarker reagents and kits combined with growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the primary factor boosting the market growth during the forecast period.

Troponin I and T is anticipated to be the fastest-growing segment in the cardiac marker testing market

The large share of this segment can be attributed to high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

The myocardial infarction segment is likely to dominate the market during the forecast period

The key factors such as the growing incidence of cardiovascular diseases coupled with the rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases across the globe are boosting the growth of the market.

The laboratory testing segment is likely to dominate the market during the forecast period

The key factors such as growing funding from public and private organizations for research on cardiac biomarkers coupled with ongoing clinical trials for the identification of novel cardiac biomarkers are boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10254/

Competitive Landscape

The key players in the global cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), Tosoh Corporation (Japan).

Global Cardiac Marker Testing Market Segmentation

By Product

• Reagents & Kits
• Instruments

By Biomarker Type

• Troponin I and T
• CK-MB
• Bnp or Nt-Probnp
• Hscrp
• Others

By Disease

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Ischemia

By End User

• Laboratory Testing
• Academic Institutes
• Point of Care Testing Facilities

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10254/

Global Cardiac Marker Testing Market: Recent Developments

• May 2020, Roche acquired Stratos genomics to further develop DNA.
• April 2019, Roche diagnostics launched the VITROS high-sensitivity Troponin I assay.
• May 2019, Abbott launched the next generation smartphone connectable confirm RX, which FDA and CE Mark accept for implantable continuous cardiac monitoring. It is for quick and early diagnosis of remote monitoring heart problems.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the clinical chemistry analyzers market is expected to grow rapidly over the next 10 years to reach a value of more than the US $19.7 billion by 2031.

Clinical chemistry analyzers are used to calculate the concentration of certain electrolytes, metabolites, and drugs in serum, cerebrospinal fluid, and other body fluids among others. It creates an accurate result within the lease period and is planned for extremely advanced technology. It is used to validate health conditions like nutritional status, liver functions, and kidney functions among others. Different types of tests such as lipid profile, liver panel, and a renal panel comprising therapeutic drugs are used to enhance metabolic functions. Rising demand for clinical tests and the increasing prevalence of endocrine diseases are the major factors driving the growth of the market.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10255/

Global Clinical Chemistry Analyzers Market: Key Drivers

The key factor propelling the growth of the market is the rising geriatric population coupled with the increasing prevalence of chronic and lifestyle diseases. The increasing geriatric population in developed and developing regions will positively influence the growth of the clinical chemistry analyzers market. Owing to rapid growth in the elderly population, the prevalence of age-associated diseases like hypertension, diabetes, cardiovascular, liver, and kidney diseases are anticipated to increase significantly. The diagnosis and management of such diseases are responsible for the rising number of prescriptions for tests like basic metabolic panel, lipid profile, and liver & renal panel. The growth in chronic illnesses will increase the demand for tests prescribed for the prevention, diagnosis, and treatment of the same. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for clinical chemistry analyzers during the projection period. These tests are performed by clinical chemistry analyzers; so, it is expected to have a positive impact on this market.

Report Findings

The reagents segment is likely to dominate the market during the forecast period

The recurrent requirement of reagents in large numbers as compared to analyzers is the primary factor boosting the growth of this segment.

The basic metabolic panel tests segment accounted for the largest share during the forecast period

This can be attributed to the increasing incidence of diabetes and other lifestyle and chronic diseases and the increasing trend of preventive healthcare.

The hospitals & clinics segment is likely to dominate the market during the forecast period

The key factors such as growing adoption of point of care testing devices coupled with increasing demand for laboratory automation is propelling the market growth.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10255/

Competitive Landscape

The key players in the global clinical chemistry analyzers market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).

Global Clinical Chemistry Analyzers Market Segmentation

By Product

• Reagents
• Analyzers
• Others

By Test Type

• Basic Metabolic Panels
• Liver Panels
• Renal Panels
• Lipid Profiles
• Thyroid Function Panels
• Electrolyte Panels
• Specialty Chemical Tests

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Laboratories & Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10255/

Global Clinical Chemistry Analyzers Market: Recent Developments

• January 2020, Sysmex invested in Astrego Diagnostics for the development of urinalysis solutions.
• July 2019, Trivitron Healthcare introduced the ‘Nanolab 200,’ a fully automated chemistry analyzer. The new product is an automated benchtop chemistry analyzer with a throughput of approximately 200 tests per hour. The newly launched product, which is integrated with cutting-edge liquid level detection technology, is anticipated to improve efficiency levels in clinical laboratories.
• December 2018, BIOBASE Group launched BK200 mini auto chemistry analyzer for small laboratories and clinics to meet the needs of its customers.
• November 2017, Roche Diagnostics acquired Viewics (US) to expand its leading position in the integrated core lab space with business analytics capabilities.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cancer biomarkers market is expected to grow rapidly over the next 10 years to reach a value of more than the US $63.6 billion by 2031.

Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body, estimated by collecting samples such as stool, tumor tissue, blood, urine, or other tissues or bodily fluids. Biomarkers may be formed by the cancer tissue itself or by other cells in the body in response to cancer. They enhance cancer detection and assist in high-speed noninvasive diagnosis using genomics and proteomics.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10251/

Global Cancer Biomarkers Market: Key Drivers

The key factor boosting the growth of the market is rising technological advancements in the development of cancer biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to great extent.

Similarly, the growing preference for personalized medicine is also boosting the growth of the market. Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. So, the field of personalized medicine is likely to offer potential growth opportunities for players operating in the cancer biomarkers market.

Report Findings

The protein biomarker segment is likely to dominate the market during the forecast period

The key factors such as increasing research on cancer biomarkers are propelling the growth of the market.

The breast cancer segment is anticipated to dominate the market during the forecast period

The key factors such as the increasing incidence of cancer across the globe are boosting the growth of the market.

The omics technologies are estimated to dominate the market during the forecast period

The key factors such as the increased use of cancer biomarkers for new developments are boosting the growth of this segment.

The diagnostic segment is likely to dominate the market during the forecast period

The factors such as an increase in the application of cancer biomarkers for companion diagnostics will boost the market growth during the forecast period.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10251/

Competitive Landscape

The major key players in the cancer biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

Global Cancer Biomarkers Market Segmentation

By Biomarker Type

• Protein Biomarker
• Genetic Biomarker
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Others

By Profiling Technologies

• Omics Technologies
• Imaging Technologies
• Immunoassays
• Bioinformatics
• Cytogenetics

By Application

• Diagnostics
• Research & Development
• Prognostics
• Risk assessment
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10251/

Global Cancer Biomarkers Market: Recent Developments

• February 2022, Onco DNA introduced the Onco Deep Solid Tumor Biomarker Test Kit. The Onco Deep kit, which comprises Twist Bioscience’s enrichment and library preparation solutions, will give labs a complete and reliable solution for performing comprehensive NGS analysis of tumor samples.
• April 2021, F. Hoffmann-La Roche Ltd., launched Elecsys Anti-p53 immunoassay to assist in the diagnosis of various cancer types.
• December 2020, Thermo Fisher Scientific (US) received FDA approval for NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
• April 2020, Qiagen N.V. launched the therascreen BRAF test as a companion diagnostic to a BRAFTOVI-based regimen in metastatic colorectal cancer.
• May 2019, Biotech Support Group (BSG) and Leiden University Medical Center (LUMC) have established a research partnership to identify stromal conditioning biomarkers in Cancer.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the clinical trial imaging market is expected to grow rapidly over the next 10 years to reach a value of more than the US $2.1 billion by 2031.

Clinical Trial Imaging comprises the use of imaging modalities, analysis services, and software to effectively determine the efficacy of novel medications prior to commercial release. Clinical Imaging techniques are increasingly used in oncology drug clinical trials to provide evidence for the drug’s effectiveness and safety. The imaging systems commonly used in clinical trials comprise Positron Emission Tomography (PET), Optical Coherence Tomography (OCT), Magnetic Resonance Imaging (MRI), and Ultrasound. The growth in the number of cancer diagnoses and deaths worldwide is estimated to drive the market during the projection period. However, the stringent government regulations in the sector are projected to restrict growth opportunities for the Clinical Trial Imaging Industry.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10256/

Global Trial Imaging Analyzers Market: Key Drivers

The key factor such as an increase in R&D spending is an increase in R&D spending. Pharmaceutical and biotechnology companies invest heavily in research to develop breakthrough molecules. Growth in the R&D expenditure by pharmaceutical & biotechnology companies and governments combined with the increasing focus on life science projects to develop new therapeutic & diagnostic products is estimated to boost the clinical trial imaging market. Likewise, developing countries such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the clinical trial imaging market, mainly owing to the growing R&D funding in these countries. These developing markets also have a strong trend of commercialization of life science research. With significant developments in life sciences research, these economies are anticipated to offer high growth opportunities in the clinical trial imaging market. Moreover, Asian markets, especially China and India, have many CROs that offer drug discovery services to pharmaceutical and biotechnology companies. With the significant increase in R&D funding and CROs operating in emerging countries, the demand for clinical trial imaging is anticipated to boost in these countries in the upcoming years.

Report Findings

The service segment accounted for the largest share of the clinical trial imaging market in 2021

mainly owing to the increase in R&D spending and growth in the pharmaceutical and biotechnology industries.

The computed tomography segment accounted for the largest share

Factors such as the rising number of CROs, increasing R&D spending, and growth in pharmaceutical & biotechnology industries drive this market.

The oncology segment is likely to dominate the market during the forecast period

Factors such as rising R&D spending and growth in pharmaceutical & biotechnology industries are driving the market growth.

The pharmaceutical companies segment accounted for the largest share in the market

The growth in the pharmaceutical & biotechnology companies coupled with an increasing number of CROs and an increase in R&D spending is boosting the growth of the segment.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10256/

Competitive Landscape

The key players in the global clinical trial imaging market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace Klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US).

Global Clinical Trial Imaging Market Segmentation

By Products & Services

• Services
• Software

By Modality

• Computed Tomography
• Magnetic Resonance Imaging
• Ultrasound
• Positron Emission Tomography
• X-ray
• Echocardiography

By Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• CVS
• Endocrinology
• Immunological Disorder

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Manufacturer
• Contract Research Organizations
• Academic & Government Research Institutes

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Rest of World
• Latin America
• Middle East
• Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10256/

Global Clinical Trial Imaging Market: Recent Developments

• May 2021, IXICO Plc signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.
• February 2021, ICON Plc acquired PRA Health Science to strengthen its global healthcare intelligence and clinical research business.
• February 2021, Resonance Health Ltd received CE mark clearance for Hepa Fat AI software for commercialization in the European market.
• January 2021, Bioclinica announced the release of Image Redact AI. Bioclinica is an integrated solutions provider of clinical life science and technology expertise.
• January 2021, Bioclinica acquired Silicon Valley-based Saliency. Bioclinica will integrate the company’s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. The integration will dramatically accelerate image QC and interpretation, enabling the rapid development of digital diagnostics and digital therapeutics.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cancer diagnostics market is expected to grow rapidly over the next 10 years to reach a value of more than the US $43.7 billion by 2031.

Cancer diagnostics is a method of identifying different diagnostics, proteins, and some signs that leads to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule & review treatment outcomes. Diagnostic procedures for cancer may comprise imaging, tumor biopsy, laboratory tests (comprises tests for tumor diagnostics), endoscopic examination, surgery, or genetic testing.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10252/

Global Cancer Diagnostics Market: Key Drivers

The key factor boosting the growth of the market is the growth in the number of private diagnostic centers. The number of private diagnostic centers is increasing across the world as there is a rising demand for diagnostic imaging procedures and a growing burden on public hospitals owing to the limited number of imaging modalities at their disposal. In January 2021, FUJIFILM Corporation opened NURA, a medical screening center focusing on cancer screening in Bangalore, India. This medical screening center is run by FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty’s Healthcare (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a joint venture of FUJIFILM and Dr. Kutty’s Healthcare (DKH), which runs hospitals and screening centers in India and the Middle East.

Report Findings

The consumables segment is likely to dominate the market during the forecast period

The repeated purchase coupled with high consumption, and the high prevalence of diseases are the major factor boosting the growth of this segment.

The IVD testing segment is likely to dominate the market in 2021

The key factors such as increasing incidences of cancers are boosting the growth of the market.

The breast cancer segment is likely to continue its dominance during the forecast period

The key factors such as the rising prevalence of breast cancer are boosting the market growth.

The hospital segment is likely to acquire a major market share during the forecast period

The increasing number of patients visiting hospitals, the rising number of in-house diagnostic procedures performed in hospitals coupled with growing awareness regarding early diagnosis are the major factor boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10252/

Competitive Landscape

The key players analyzed in the global cancer diagnostics market are GE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US), Siemens Healthineers AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Cancer Diagnostics Inc. (US), Vela Diagnostics (Singapore), Roche Diagnostics (Switzerland), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (US), Bio SB (US), Biocartis NV (Belgium), Exact Science (US).

Global Cancer Diagnostics Market Segmentation

By Product

• Consumables
• Instruments

By Technology

• IVD Testing
• Imaging
• Biopsy Technique

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Other Cancers

By End User

• Hospitals
• Diagnostic Laboratories

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Rest of World
• Latin America
• Middle East
• Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10252/

Global Cancer Diagnostics Market: Recent Developments

• November 2020, GE Healthcare entered into a partnership with Genesis Care to improve patient outcomes for the two biggest health burdens across the globe, cancer and heart diseases. GE Healthcare will provide CT, MRI, PET/CT, digital mammography, and ultrasound equipment to Genesis Care’s 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain.
• January 2020, Roche Diagnostics entered into a partnership with Illumina to provide broad access to clinical oncology next-generation sequencing.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the capnography equipment market is expected to grow rapidly over the next 10 years to reach a value of more than the US $530.3 million by 2031.

Capnography equipment is conventionally used for cardiology surgeries for patients under deep sedation and anesthesia. Still, with the increasing number of target patients for critical applications such as trauma and emergency cases, the demand for portable/point-of-care capnography equipment is expected to increase. In line with this changing market trend, key market players are primarily focusing on developing portable/point-of-care or handheld capnography equipment that can be used for such applications that require easy device mobility and patient access.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10253/

Global Capnography Equipment Market: Key Drivers

The key factors such as the development of portable/POC capnography devices. In the initial stages, healthcare professionals can identify potential breathing complications (like airway obstruction, hyperventilation, hypoventilation, or apnea) through ventilation monitoring or capnograph evaluation of target subjects. Real-time measurement of various respiratory parameters helps healthcare professionals decide on patient treatment options and enables timely intervention at the onset of an adverse respiratory event.

Report Findings

The capnometers segment is likely to dominate the market during the forecast period

The rising adoption of capnography equipment, recommendations for its use in patient monitoring, medical reimbursements for capnography equipment across developed countries, and the rising number of surgical procedures are boosting the growth of the market.

The mainstream capnography segment is estimated to dominate the market during the forecast period

The advantages associated with mainstream capnography, like the ease of use and the ability to monitor breathing in intubated patients precisely, are likely to boost the growth of this market.

The cardiac surgery segment is anticipated to dominate the market during the forecast period

The large share of this segment is attributed to the increasing regulatory guidelines recommending capnography for cardiac surgeries coupled with the rising number of cardiopulmonary surgeries performed across the globe.

Hospitals dominate the capnography equipment market during the forecast period

Factors such as evolving guidelines related to the use of capnography and the rising incidence of chronic disorders are likely to boost the demand for capnography equipment in hospital settings in the upcoming years.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10253/

Competitive Landscape

The key players comprised in the global capnography equipment market are ZOLL Medical (Asahi Kasei) (Japan), Becton, Dickinson, and Company (US), Drägerwerk AG & Co. KGaA (Germany), Edan Instruments, Inc. (China), GE Healthcare (US), Hamilton Medical (Switzerland), Welch Allyn (a Hill-Rom company) (US), Koninklijke Philips N.V. (Netherlands), Masimo Corporation (US), Medtronic plc (Ireland), Mindray Medical (US), Nihon Kohden (Japan), Nonin Medical Inc.(US), Schiller (Switzerland) and Smiths Medical (UK), Avante (US), Bionics (South Korea), BPL Medical Technologies (India), Burtons Medical Equipment, Ltd. (UK), Criticare Technologies, Inc. (US), Diamedica (UK), Infinium Medical (US), SunMed (US), Nidek Medical India (India), ResMed Inc. (US), RMS (India), Shenzhen Comen Medical Instruments Co., Ltd. (China), SLE Ltd. (UK), UTAS Co. (Ukraine), and Zoe Medical (US).

Global Capnography Equipment Market Segmentation

By Product Type

• Capnometers
• Capnography Accessories and Disposables

By Technology

• Mainstream
• Sidestream
• Microstream

By Application

• Cardiac Surgeries
• Trauma and Emergency Care
• Respiratory Monitoring
• Others

By End Users

• Hospitals
• Ambulatory Surgery Centers & Home Care
• Others

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Rest of World
• Latin America
• Middle East
• Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10253/

Global Capnography Equipment Market: Recent Developments

• December 2021, ZOLL Medical Corporation, an Asahi Kasei Company, closed its acquisition of Itamar Medical Ltd., an Israeli medical device manufacturer. Itamar Medical will operate as a business division within ZOLL.
• May 2020, Masimo and Philips signed a licensing agreement bringing Masimo Nomo Line Capnography and O3 Regional Oximetry to select Philips’s patient monitors. Philips will integrate additional Masimo measurement technologies into select Intelli Vue MX-series multi-parameter monitors to help clinicians assess cerebral oximetry and ventilation status.
• April 2021, Masimo Corporation announced the U.S. FDA approval for Radius PCG. It is a portable real-time capnograph with wireless Bluetooth connectivity which provides seamless, tetherless mainstream capnography for patients of all ages. This approval helped the company to gain a competitive edge and strengthen its industrial position.
• December 2019, Masimo and Drager expanded their Licensing Agreement to comprise Masimo brain monitoring and capnography technologies. Dragger added Masimo nomoline Capnography measurements to its suite of advanced measurement parameters for ORs and critical care.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the breast reconstruction market is expected to grow rapidly over the next 10 years to reach a value of more than the US $748.1 million by 2031.

Breast reconstruction is an important facet of breast cancer management. It has a less cosmetic result. Breast reconstruction provides social, psychological, emotional and functional improvements, counting improved self-esteem, psychological health and body image.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10249/

Global Breast Reconstruction Market: Key Drivers

The major factor boosting the growth of the market is an increasing awareness about breast reconstruction treatment. A number of patients choose breast reconstruction surgery after mastectomy. This can be primarily attributed to the growing concerns and increasing awareness of the safety and efficacy of reconstructive surgeries. This trend can be observed in both developed and emerging countries which are experiencing improvements in the standard of living.

The growth in awareness can be credited to initiatives taken by market players and stakeholders as well as independent bodies like the American Society of Plastic Surgeons (ASPS). ASPS, along with the Plastic Surgery Foundation, organized the Breast Reconstruction Awareness campaign to engage and educate women on reconstruction post breast cancer diagnosis. The primary target of the campaign was to educate women, family members, and the media that the breast cancer loop remains open until a woman is informed of her breast reconstruction options. Other primary events include the Association of Breast Surgery Conference 2020 in England and the 36th Annual Breast Surgery Symposium held in Georgia, US. In 2011, Canada launched the first BRA Day (Breast Reconstruction Awareness Day). This year, the American Society of Plastic Surgeons and The Plastic Surgery Foundation has joined forces with the Canadians to initiate BRA Day USA. On February 17, 2022, Tata Memorial Center organized a conference – Reconstruction and Cancer Care: Enhancing Quality Living with and Beyond Cancer to create awareness regarding breast reconstruction.

Report Findings

The breast implants segment is likely to dominate the market during the forecast period

The growth of the segment is attributed to the increasing incidences of breast cancer and the rising number of breast reconstruction procedures.

The immediate segment is likely to dominate the market during the forecast period

The key factors boosting the growth of the market are the increasing number of breast reconstruction procedures combined with an increasing number of breast cancer patients.

The unilateral segment is likely to dominate the market during the forecast period

The key factors propelling the growth of the market are rapid technological advancements coupled with the high growth opportunities in emerging markets and the rising development of 3D-printed implants.

The hospital segment is likely to dominate the market during the forecast period

The development and adoption of advanced technologies for breast reconstruction are likely to drive the breast reconstruction market during the projection period.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10249/

Competitive Landscape

The global breast reconstruction market report comprises players such as Mentor Worldwide LLC (Johnson & Johnson) (US), Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), and Silimed (Brazil) among others.

Global Breast Reconstruction Market Segmentation

By Product

• Breast Implants
  • By Type
    • Silicone Implants
    • Saline Implants
  • Shape
    • Round Implants
    • Anatomical Implants
• Tissue Expanders
• Acellular Dermal Matrix

By Procedure

• Immediate
• Delayed
• Revision

By Type

• Unilateral
• Bilateral

By End User

• Hospitals
• Cosmetology Clinics and Surgical Centers

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Rest of World
• Latin America
• Middle East
• Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10249/

Global Breast Reconstruction Market: Recent Developments

• 2022, Mentor Worldwide LLC (J&J) received the US FDA approval for a new Mentor Memory Gel boost breast implant.
• 2021, POLYTECH Health & Aesthetic received US FDA approval for the company’s textured breast implants
• 2020, Sientra received US FDA pre-market approval for its OPUS-branded breast implant products

New York, June 2022: According to a new research study by Global Insight Services (GIS), the breast lesion localization market is expected to grow rapidly over the next 10 years to reach a value of more than the US $390.6 million by 2031.

Breast lesion localization is a medical device used in the detection of malignant and nonmalignant tumors. It is used in the preoperative marketing of nonpalatable breast lesions. There are different types f breast lesion localization devices developed using different techniques: radiations, wires, radar, and electromagnetic. Breast lesion localization methods are used to detect the abnormalities in terms of a lump or tumor in the breasts. There are various types of breast lesion localization methods used across the globe to detect a lump or tumor in the breasts. However, the rapid increase in the number of women opting for preventive screening tests for breast cancer creates a highly conducive environment for the growth of the breast lesion localization market.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10248/

Global Breast Lesion Localization Market: Key Drivers

The major factor boosting the growth of the market is the increasing incidence of breast cancer. Breast cancer is among the most common diseases affecting women in developed and developing countries. As per the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women globally. Worldwide, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the rising number of women undergoing cosmetic surgeries, such as breast enhancement.

Similarly, the growing rate of the aging population is also boosting the growth of the market. With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. As per the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. Conversely, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

Report Findings

The wire localization segment is likely to dominate the market during the forecast period

The increasing incidence of breast cancer combined with the increasing adoption of expansion strategies by manufacturers of lesion localization products, product launches, and increasing healthcare expenditure are a major factor driving the global breast lesion localization market.

The breast biopsy segment is likely to dominate the market during the forecast period

The key factors such as increasing consumption of alcohol and a sedentary lifestyle causing obesity are boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10248/

Competitive Landscape

The global breast lesion localization market report includes players such as Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada), Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

Global Breast Lesion Localization Market Segments

By Type

• Wire Localization
• Radioisotope Localization
• Radio-guided Occult Lesion Localization
• Radioactive Seed Localization
• Magnetic Localization
• Electromagnetic Localization
• Other Localization Methods

By Usage

• Breast Biopsy
• Breast Conservation (Lumpectomy)

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Rest of World
• Latin America
• Middle East
• Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10248/

Global Breast Lesion Localization Market: Recent Developments

• January 2021, Hologic Inc., has completed the acquisition of Somatex Medical Technologies, which will enable Hologic Inc to strengthen its breast markers portfolio.
• October 2020, Endomagentics Ltd launched a product called Magseed, which is implanted in the affected breast prior to the surgery, and through the use of a probe, can point out to the surgeon where exactly the cancerous tissue is located.
• January 2019, IZI acquired Cook’s product portfolio of soft-tissue biopsy and breast localization needles. This will enable IZI to capture newer markets.
• November 2018, Merit Medical System Inc. has completed acquisition of Cianna Medical Inc. and its breast cancer localization and guidance devices, which adds to Merit, a technology leader in breast tumor localization.

New York, May 2022: According to a new research study by Global Insight Services (GIS), the bone growth stimulators market is expected to grow rapidly over the next 10 years to reach a value of more than the US $2 billion by 2031.

Bone Growth stimulators are devices that are used to boost the healing process during the treatment of the ailments such as spinal fixation, and orthopedic fixation. Bone growth stimulators work on all kinds of fractures such as fresh fractures, fractures healing slowly or not at all, and fractures with an elevated risk. It can also be used as supportive therapy after surgery on a fracture and in the corrective osteotomy. Bone Growth Stimulator enhances the healing process by stimulating the production of new cells, which will allow your fracture to heal considerably faster. Bone growth stimulators are the perfect treatment approach when the patient is not comfortable with the surgical procedure and wants to avoid it. Also, as it fastens the healing process, it helps patients get back to their feet quickly. Bone growth stimulators have revolutionized the treatment of bone fractures and spinal fusions and are becoming an important tool in the healing process. Advantages over surgical procedures, faster recovery time, and increasing patient preference are factors that contribute to the growth of the bone growth stimulator market.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10246/

Global Bone Growth Stimulators Market: Key Drivers

The key factor boosting the growth of the market is the growing patient preference for non-invasive and minimally invasive surgical treatments. The demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key advantages of minimally invasive procedures comprise fewer complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infections, reduced postoperative care, and quicker recovery. Minimally invasive procedures make use of advanced technologies to diagnose and treat various diseases, comprising cancer. These procedures are used as an effective approach for removing cancer tumors and lymph nodes without scarring.

Similarly, emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities in the bone growth stimulators market. Factors such as the presence of a large patient population, rising healthcare expenditure, government initiatives to support the healthcare industry, strengthening export trade, and growing awareness among physicians, surgeons, and patients about the latest treatment options for spinal fusion and bone healing are expected to boost the demand for bone growth stimulation products in these countries. In addition, owing to the significant cost advantages, many patients from developed markets are reported to travel to these emerging markets to undergo medical treatment.

Report Findings

The bone growth stimulation devices segment accounted for the bone growth stimulators market

This can be attributed to the growing geriatric population, rising preference for non-surgical treatment procedures, and growing prevalence of nonunion fractures. Adding to that, obesity, smoking, and diabetes, among other factors, can delay or inhibit bone healing after surgery or trauma. The growing incidence of these risk factors will further help the market growth.

Bone growth stimulation products are used at the time or post-surgery for stimulating the natural bone growth process

The growth of this segment can be attributed to the increasing population, the growing number of spine procedures, the established safety and efficacy of stimulators in fusion surgery, and the increasing use of bone growth stimulation products.

The hospitals & ASCs accounted for the largest share of the bone growth stimulators market

The advantages of bone growth stimulation products over their counterparts, the growing prevalence of spinal disorders, and growing awareness of bone growth stimulation products are the key factors boosting the bone growth stimulators markets for hospitals and ASC’s.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10246/

Competitive Landscape

The global bone growth stimulators market report comprises key players such as Orthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health Inc. (Canada), VQ OrthoCare (US), Kinex Medical Company, LLC (US), Fintek Bio-Electric Inc. (Canada), Biomedical Tissue Technologies Pty Ltd. (Germany), T-Biotechnology (Turkey), DrPRP America LLC (US), Ivy Sports Medicine, LLC (US), Glofinn Oy (Finland), and REMI GROUP (India) among others.

Global Bone Growth Stimulators Market Segmentation

By Product

• Bone Growth Stimulation Devices
• Bone Morphogenic Proteins
• Platelet-Rich Plasma

By Application

• Spinal Fusion Surgeries
• Delayed Union and Nonunion Bone Fractures
• Oral and Maxillofacial Surgeries
• Others

By End User

• Hospitals & ASC’s
• Home Care Settings
• Academic & Research Institutes

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10246/

Global Bone Growth Stimulators Market: Recent Developments

• April 2021, Orthofix entered into an exclusive license agreement to commercialize the innovative portfolio of IGEA’s bone, cartilage, and soft tissue stimulation products in the US and Canada.
• March 2021, Bioventus LLC announced the acquisition of Bioness, Inc. This acquisition will enable Bioventus LLC to expand its bone growth therapy product portfolio.
• November 2020, Stryker acquired Wright Medical for USD 5.4 billion. The acquisition strengthened Stryker’s position in the orthopedics devices market.
• June 2020, DePuy Synthes renewed its agreement with AO Foundation to improve patient care and outcome through innovation and AO’s independent global education offerings.
• February 2020, Orthofix Medical Inc. received US FDA approval for its STIM on Track, mobile app version 2.1 to advance the treatment with its bone growth stimulators like Cervical Stim, Spinal Stim, and Physio Stim.
• January 2020, Medtronic acquired Stimgenics to expand its portfolio in the Differential Target Multiplexed Spinal Cord Stimulation Therapy.

New York, May 2022: According to a new research study by Global Insight Services (GIS), the blood screening market is expected to grow rapidly over the next 10 years to reach a value of more than the US $2.8 billion by 2031.

Blood screening is a medical process in which blood is examined for a specific disease or condition. It aids in monitoring disease and preventing health issue and a variety of other conditions such as infection and cancer. Human Immunodeficiency Virus (HIV), blood type, and pregnancy screenings are the most common types of blood screening.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10245/

Global Blood Screening Market: Key Drivers

The key factor boosting the market growth is an increasing number of blood donations across the globe. There is an increase in the need for donated blood owing to advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, like cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. On an average around 235 million major surgeries are being performed across the globe every year, of which 63 million are traumatic surgeries, cancer-related are over 31 million, and 10 million are related to pregnancy complications. Blood transfusion is generally prescribed in complicated childbirth to prepare for childhood congenital maternal blood disorders, acute anemia, and trauma.

Similarly, emerging markets such as India, the Middle East, and Africa offer promising opportunities for players in the blood screening industry owing to their rising disposable incomes and improving healthcare infrastructure. For example, according to Statista (August 2021), in 2017 India’s healthcare was worth about USD 160 billion, and it was anticipated to reach USD 372 billion by 2022 owing to rising income levels, increasing awareness about health, and the incidences of lifestyle diseases are growing year by year. Currently, the widely used technology in India is ELISA, because NAT registered relatively low penetration. Unlike the US, Canada, most of Europe, Japan, Korea, Singapore, Sri Lanka, the UAE, South Africa, Thailand, and China; NAT is still not mandatory in India. Almost 100 blood banks, comprising AIIMS, PGI Chandigarh, CMC Vellore, Medanta-The Medicity, and Narayana Hrudayalaya, are using NAT in ID-NAT format, whereas around 40 blood banks are using the pooling technique. So, an initiative is taken by the Indian government to train doctors, hospitals, and blood banks on using NAT.

Report Findings

The reagents and kits segment is likely to dominate the market during the forecast period 2022-2031

The increase in blood transfusion procedures leads to the higher consumption and frequent use of reagents & kits in blood screening procedures. Is boosting the growth of the market.

The nucleic acid test segment is likely to dominate the market in 2021

The key factors such as increasing adoption of NAT technology owing to higher sensitivity over other blood donations are boosting the growth of the market.

The blood bank segment is likely to dominate the market during the forecast period

The increasing number of organ transplantation surgeries is boosting the growth of this segment during the forecast period.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10245/

Competitive Landscape

The global blood screening market report comprises key players such as Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).

Global Blood Screening Market Segments

By Product & Services

• Reagents & Kits
• Instruments
• Software & Services

By Technology

• Nucleic Acid Test
• ELISA
• Rapid Tests
• Western-Blot Assays
• Next-Generation Sequencing

By Technology

• Blood Banks
• Hospitals

By Regions

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10245/

Global Blood Screening Market: Recent Developments

• June 2021, Grail, announced the launch of the Galleri Blood test, the company’s innovative multi-cancer screening diagnostic capable of detecting the presence of multiple cancers. This test will help the company screen around 50 million people after its launch and pursue a full FDA approval by 2023.
• May 2021, Tzar Labs, announced early detection cancer tests. This test will aid in determining the different stages of the disease and will be launched by the end of this year. The company’s accuracy rates are very high for screening of cancer and had shown results for all types of cancers.
• May 2021, Beckmann Coulter launched the SARS-CoV-2-IgG test to assess antibody immune response levels.
• September 2021, Roche Diagnostics acquired TIB Molbiol Group. This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
• February 2020, BD acquired NAT Diagnostics, this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.

New York, May 2022: According to a new research study by Global Insight Services (GIS), the blood collection devices market is expected to grow rapidly over the next 10 years to reach a value of more than the US $10.8 billion by 2031.

Blood collection devices help in the safe withdrawal of blood. Blood is collected from donors to perform various diagnostic tests. Needles & rings, lancets, and other devices are used for arterial and venous blood collection. Arterial blood collection has certain advantages like arterial blood gas sampling and intraoperative blood salvage. However, the growing number of accidents & trauma cases, rising incidence of infectious disease, and the developing liquid biopsy technology have improved associated healthcare processes. However, the shortage of qualified personnel will impede the market growth. Moreover, the growth opportunities among emerging nations are likely to offer significant opportunities for the growth of the global blood collection devices market.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10243/

Global Biosurgery Market: Key Drivers

The major factor boosting the growth of the market is the increasing prevalence of infectious diseases with the emergence of newer pathogens and chronic & lifestyle diseases. The increasing prevalence of infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), malaria, syphilis, and brucellosis are a major factor driving the demand for effective blood collection (owing to the risk of disease transmission during blood transfusion). According to the WHO, (July 2021), there were an estimated 37.7 million [30.2–45.1 million] people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region. In 2020, 680,000 [480,000–1.0 million] people died from HIV-related causes, and 1.5 million [1.0–2.0 million] people acquired HIV. Adding to that, according to the WHO (July 2021), worldwide, there were an estimated 7 million new syphilis infections in 2020.

The burden of chronic diseases is rapidly increasing across the globe. Almost half of the total chronic disease deaths are attributable to cardiovascular disease (CVD). In the US alone, as per the American Heart Association, the prevalence of CVD is projected to increase from 36.9% in 2010 to 38.7% by 2020 and 40.5% by 2030. Obesity coupled with diabetes is also showing worrying trends because they already affect a large proportion of the population and because they have started to appear earlier in life. The prevalence of lifestyle diseases is also growing across the world, particularly in emerging countries.

This scenario has ensured greater adherence to health check-ups combined with the growing importance of markers to find disease conditions mainly via blood collection. Health check-ups are gaining popularity both at a personal level as well as performed at a corporate level for employee well-being. This will be favorable for the market growth and a significant contributor to the blood collection devices market, as blood tests are a primary approach to diagnosing these diseases.

Report Findings

Blood collection tubes witnessing a great demand during the forecast period

owing to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders, cancers such as leukaemia, lymphoma, myeloma, and myelodysplastic syndrome can affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system.

The manual blood collection segment is likely to dominate the market during the forecast period

The increasing number of accidents, as well as trauma cases worldwide, will witness lucrative growth opportunities during the forecast period.

The hospitals & clinics segment is likely to dominate the market during the forecast period

The key factors such as increasing demand for blood donations are also fuelling the demand of the blood collection devices market. For example, according to WHO, 112.5 million blood donations collected globally and there is an increase of 10.7 million blood donations from unpaid donors has been reported from 2008 to 2013.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10243/

Competitive Landscape

The global blood collection devices market report includes players such as Becton, Dickinson and Company (US), Haematonics (US), Terumo BCT (US), Fresenius Kabi AG (Germany), Grifols, S.A. (Spain), Nipro Medical Corporation (Japan), Greiner Holding (Austria), Quest Diagnostics (US), SARSTEDT AG & Co. (Germany), Macopharma (France), Smiths Medical (US), Cardinal Health (US), Retractable Technologies (US), Liuyang Sanli Medical Technology Development (China), F.L. Medical S.R.L (Italy), AB Medical (South Korea), APTCA SPA (Italy), Jiangsu Micsafe Medical Technology CO., LTD. (China), Disera Tibbi Malzeme Lojistik Sanayi Ve Ticaret A.Þ (Turkey), Ajosha Bio Teknik Pvt. Ltd. (India), Preq Systems (India), CML Biotech (India), Lmb Technologie GmbH (Germany), Mitra Industries Private Limited (India) and Neomedic Limited (UK).

Global Blood Collection Devices Market Segments

By Product

• Blood Collection Tubes
• Plasma Separation Tube
• Heparin Tubes
• Serum Separation Tubes
• EDTA Tube
• Rapid Serum Tubes
• Coagulation Tubes
• Others
• Needles and Syringes
• Others

By Product

• Manual Blood Collection
• Automated Blood Collection

By End User

• Hospitals & Clinics
• Diagnostic & Pathology Centers
• Blood Banks
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10243/

Global Blood Collection Devices Market: Recent Developments

• February 2022, Abacus dx launched the newest addition to Streck’s trusted blood collection tube portfolio, RNA Complete BCT.
• February 2022, BD has released UltraSafe Plus 2.25 mL, a new needle guard solution that improves the delivery of drugs and other biologic solutions,
• August 2021, Quest Diagnostics Incorporated has acquired Boca Raton based Nationwide Laboratory Services. With the acquisition, Quest will broaden access to diagnostic innovation and insights empowering better health for more communities in South Florida.
• June 2021, Greiner Bio-One introduced MiniCollect PIXIE Heel Incision Safety lancet for expanding its portfolio with a new safety lancet specially designed for heel incision and now has three different lancet types of offers to cover individual needs.
• April 2021, Terumo Blood an Cell Technologies and CSL Plasma announced collaboration to deliver a new plasma collection platform.
• November 2020, Intravactechnology OU introduced new packaging system for its blood collection devices set. The packaging is available in paper, plastic blister, and foil pack for 1,2, and 5 tube pack.
• July 2020, Mangolia Medical launched Steripath Gen 2 with integrated syringe, addressed to the patient with difficult intravenous access or the ‘hard stick’ patient population.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the blood culture tests market is expected to grow rapidly over the next 10 years to reach a value of more than the US $8.5 billion by 2031.

Blood Culture tests play a essential role in the diagnosis of various infectious diseases. The increasing prevalence of infectious diseases combined with advancements in diagnostic technologies is anticipated to boost market growth. Adding to that, ageing population, demand for rapid analysis and treatment are estimated to fuel the blood culture tests market in future. According to the World Health Organization, every year around 17 million people around the world die owing to infectious diseases. Moreover, an increase in R&D investments and awareness in early diagnosis among the population across the globe is projected to foster the market growth in the near future. However, the lack of skilled professionals and high cost of novel technologies anticipated to hamper the market growth.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10244/

Global Blood Culture Tests Market: Key Drivers

The key factors such as high incidence of blood stream infections is likely to boost the growth of the blood culture tests market. Nosocomial (hospital-acquired) bloodstream infections are one of the major causes of mortality across the world. In the US alone, approximately 250,000 cases of hospital-acquired BSIs occur each year. Worldwide, bloodstream infections affect about 30 million people leading to 6 million deaths, with 3 million newborns and 1.2 million children suffering from sepsis annually. In Eastern African countries, the proportion of patients with bloodstream infections is reported to range from 11% to 28%. In Ghana, bloodstream infection rates are estimated to be in the range of 9.3% to 11.2%. The occurrence of these infections raises the overall duration of hospitalization coupled with the cost of treatment. With the rising incidence of BSIs, the demand for advanced blood culture techniques that assist in the early detection of infections is expected to raise.

Likewise, emerging economies like China, India, and other countries in Southeast Asia and countries in the Middle East and Latin America are becoming focal points for the growth of the blood culture tests market. The major growth in these markets can primarily be attributed to the growth in the prevalence of infectious diseases, rapid growth in the geriatric population, the growing number of product approvals, and rising healthcare expenditure. For example, the healthcare expenditure in China increased to 5.35% of the GDP in 2018 from USD 4.88% of GDP in 2015. Such significant spending will result in the adoption of advanced systems, such as automated blood culture systems, among hospital and reference laboratories in these regions. This, in turn, is likely to provide potential growth opportunities for players operating in the blood culture tests market in the upcoming years.

Report Findings

The conventional/manual methods segment is likely to dominate the market during the forecast period

The key factors such as growing number of sepsis cases coupled with high cost of treatment is likely to boost the growth of the market. Similarly, rising geriatric population is also refueling the growth of the global blood culture tests market.

The consumables segment is estimated to dominate the market during the forecast period 2022-2031

The key factors such as frequent demand of consumables as compared to instruments is the key factor driving the growth of this segment.

The culture-based technology segment is likely to dominate the market during the forecast period

The key factors such as increase in prevalence of infectious diseases, bloodstream infections, and sepsis, and surge in demand of diagnostic tests are the key factors that drive the growth of the market.

The bacteremia segment is likely to dominate the market during the forecast period

The increasing number of bloodstream infections and the rising number of sepsis cases across the globe is propelling the growth of the market

The hospital laboratories segment is likely to dominate the market during the forecast period

The key factors such as increasing aging population, rise in product approvals and launches combined with growing number of sepsis cases, high incidences of bloodstream infections, increase in demand for rapid diagnostic techniques and high prevalence of infectious diseases are boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10244/

Competitive Landscape

The global blood culture tests market report includes such as Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), bioMérieux SA (France), Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US), Anaerobe Systems, Inc. (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), BINDER GmbH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio, Inc. (US), Axiom Laboratories (India), and HiMedia Laboratories Pvt. Ltd. (India).

Global Blood Culture Tests Market Segments

By Type

• Conventional/Manual Methods
• Automated Methods

By Product

• Consumables
• Instruments
• Software & Services

By Technology

• Culture-based Technology
• Molecular Technologies
• Microarrays
• PCR
• PNA-FiSH
• Proteomics Technology

By Application

• Bacteremia
• Fungemia
• Mycobacterial Detection

By End User

• Hospital Laboratories
• Reference Laboratories
• Academic Research Laboratories
• Other Laboratories

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10244/

Global Blood Culture Tests Market: Recent Developments

• October 2021, Thermo Fisher Scientific and Q-Linea launched ASTar System, a rapid antimicrobial susceptibility testing system to produce true minimum inhibitory concentration (MIC) results in 6 hours.
• March 2020, Mangolia Medical Technologies announced that it received clearance from U.S. regulators for its expanded line of blood contamination reduction products, comprising Steripath Gen2 Initial Specimen Diversion Device.
• February 2020, BD (US), had an agreement with Babson Diagnostics (US). The companies signed an agreement to enable small-volume blood collection for diagnostic testing in retail settings.
• April 2019, bioMerieux SA, partnered with Wellcome Trust (UK), to coordinate VALUE-Dx, a European public-private partnership to fight antimicrobial resistance through diagnostics.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the cornea and corneal implants market is expected to grow rapidly over the next 10 years to reach a value of more than the US $420 million by 2031.

A cornea transplant (keratoplasty) is a surgical procedure to substitute part of the cornea with corneal tissue from a donor. The cornea is the transparent, dome-shaped surface of the eye. It’s where light enters the eye and is a large part of the eye’s ability to see clearly. A cornea transplant may restore vision, reduce pain, and improve the appearance of a damaged or diseased cornea. Most cornea transplant procedures are successful. But cornea transplant carries a small risk of complications, like the rejection of the donor cornea.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10239/ 

Cornea and Corneal Implants Market: Key Drivers

Increasing Prevalence of eye diseases

The number of people with major eye diseases is increasing worldwide, and vision loss is becoming a major public health concern. The growth in the aging population coupled with the increasing prevalence of chronic disorders like diabetes and hypertension have raised the prevalence of eye diseases such as diabetic retinopathy and ocular hypertension (glaucoma). The number of blind individuals or those affected with low vision is also expected to increase extensively. According to the Royal National Institute of Blind People (RNIB), in 2013, around 2 million people in the UK were living with vision loss, and this figure is likely to increase to 4.1 million by 2050. Presently, there are 146 million people worldwide with trachoma, of which 10 million suffer from trichiasis and need surgery to prevent corneal blindness and 4.9 million individuals are completely blind from trachomatous corneal scarring. Moreover, as per the “World Report on Vision 2019” by WHO, nearly 2.2 people worldwide have vision impairment or blindness. This figure includes several eye conditions that include moderate to severe distance vision impairment or blindness owing to unaddressed refractive errors (123.7 million) and presbyopia (1.8 billion, including both addressed and unaddressed presbyopia), age-related macular degeneration (10.4 million), cataract (65.2 million), corneal opacities (4.2 million), glaucoma (6.9 million), trachoma (2 million), diabetic retinopathy (3 million), and other causes (37.1 million), and people with mild vision impairment with unknown causes (188.5 million).

Shortage of corneal donors

There is a significant requirement for corneal donors across the globe, as approximately 10 million people need corneal transplants. Densely populated counties such as India suffer from a significant shortage of donor corneas, and there is a waiting period of more than six months for corneal transplants among patients suffering from corneal blindness. Approximately 6.8 million people in the country have poor vision in one eye, and nearly one million people have poor vision in both eyes due to corneal disorders. It was anticipated that by the end of 2020, India would suffer from 10.6 million cases of unilateral corneal blindness. In 2019, around 120,000 people were affected by corneal blindness. About 250,000 corneas are needed annually in the country; still, the total number of corneas donated each year is around 25,000. The high burden of corneal blindness, combined with a shortage of corneal donors, is likely to offer high-growth opportunities to manufacturers of corneal implants.

Report Findings

The human cornea segment is likely to hold a major market share during the forecast period.

The key factors boosting the growth of the market are rising awareness regarding corneal transplantation and eye tissue donations majorly in developing countries.

The penetrating keratoplasty segment is likely to hold the majority of the market share during the forecast period.

The factors boosting market growth are the rising number of people suffering from eye disorders such as infectious keratitis and injury of the eyeball.

The fuchs’ dystrophy segment is likely to hold a major market share during the forecast period.

The key factors such as the increasing incidence of the disease and the growing awareness among people regarding early disease diagnosis are driving the market growth.

The hospitals & ambulatory surgical centers segment is likely to dominate the global cornea and corneal implant market during the forecast period.

The key factors such as rising incidences of corneal blindness coupled with increasing cases of trauma cases is propelling the growth of the global cornea and corneal implant market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10239/ 

Competitive Landscape

The key players in the global cornea and corneal implants market are AJL Ophthalmic, CorneaGen Inc, CorNeat Vision, LinkoCare Life Sciences AB, Presbia plc, Mediphacos, Aurolab, Cornea Biosciences, DIOPTEX GmbH and EyeYon Medical among others.

Cornea and Corneal Implants Market: Segments Covered

By Type

• Human Cornea
• Artificial Cornea

By Transplant Type

• Penetrative Keratoplasty
• Endothelial Keratoplasty
• Anterior Lamellar Keratoplasty
• Keratoprosthesis

By Disease Indication

• Fuschs’ Dystrophy
• Fungal Keratitis
• Keratoconus
• Others

By End Users

• Hospitals & Ambulatory Surgical Centers
• Specialty Clinics

By Regions

• North America
• Europe
• Asia Pacific
• Rest of the World

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10239/

Cornea and Corneal Implants Market: Recent Developments

• June 2020: AJL Ophthalmic received CE Mark approval for ENDO-K PRO. Product approval will enable the company to provide its portfolio to end-users.
• January 2020: Mediphacos launched Keraring Intrasomal Corneal Ring. The product launch will enable the company to capture market share.

New York, April 2022: According to a new research study by Global Insight Services (GIS), the aspiration & biopsy needles market is expected to grow rapidly over the next 10 years to reach a value of more than the US $889 million by 2031.

A needle biopsy is a procedure to obtain a sample of cells from the body for laboratory testing. Common needle biopsy procedures comprise fine-needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones, and other organs, such as the liver or lungs. The sample from needle biopsy may assist the doctor to determine what’s causing a mass or lump, an infection, and inflammation. One may undergo imaging tests, such as the computerized tomography (CT) scan or an ultrasound, before needle biopsy. Sometimes these tests are used during the needle biopsy procedure to more accurately locate the area to be biopsied.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10240/

Aspiration & Biopsy Implants Market: Key Drivers

Rising prevalence of cancer

Worldwide, there has been a significant rise in the number of people suffering from cancer. This can be indorsed to a number of factors, like lifestyle changes, unhealthy diets, and growing tobacco consumption. According to estimates from the International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths across the globe. By 2040, the global burden is anticipated to grow to 27.5 million new cancer cases and 16.3 million cancer deaths, majorly due to the growth and aging of the population.

The incidence of cancer is the highest in more-developed regions, but mortality is relatively higher in less-developed countries owing to a lack of access to treatment facilities coupled with the lack of awareness regarding the benefits of early detection. According to the American Cancer Society, about 9.6 million people die from cancer every year, and 70% of cancer deaths occur in low-to-middle income countries like China and India; these proportions are expected to grow further by 2025. With the increasing prevalence of cancer in major regions across the globe, the demand for effective cancer diagnosis is anticipated to increase in the upcoming years. This, in turn, is expected to support the growth of the aspiration and biopsy needles market during the forecast period.

Emerging economies

Emerging economies (such as India, China, Brazil, and Mexico) are anticipated to offer significant growth opportunities for players operating in the aspiration and biopsy needles market. This can be attributed to improvements in the standard of living, the presence of a huge target population base (as a result of the rising prevalence of cancer), improvements and developments in the healthcare infrastructure, rising healthcare expenditure, and the transformation of healthcare research facilities in these countries. Adding to that, the rapid economic development coupled with rising healthcare expenditure in these emerging countries have improved access to quality healthcare, including quality cancer care.

Report Findings

The biopsy needle segment is likely to dominate the market during the forecast period

The key factors such as the rising prevalence of cancer coupled with an increasing preference for minimally invasive diagnostic procedures (over excision biopsies) are boosting the growth of the biopsy needles segment in the global aspiration & biopsy needles market.

The tumor/cancer segment is likely to dominate the market during the forecast period

The higher market share is primarily attributed to the growing prevalence of breast cancer combined with rising awareness about the disease, and increasing research activity pertaining to breast screening and diagnosis is boosting the market share of the segment.

The image-guided procedure accounted for the largest share of the market during the forecast period

The key factors propelling the market growth are the rising preference for minimally invasive biopsy and aspiration procedures.

The hospitals & surgical centers segment is likely to dominate the market during the forecast period

The key factors such as the rising prevalence of cancer coupled with cancer awareness initiatives undertaken by government and global health organizations are boosting the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10240/

Competitive Landscape

The key players in the global aspiration & biopsy needles market are CONMED Corporation, Medtronic Plc, Olympus Corporation, Becton, Dickinson and Company, Boston Scientific Corporation, Cook Group Incorporated, Argon Medical Devices, Inc, INRAD Inc., Somatex Medical Technologies, Stryker Corporation, Cardinal Health, Remington Medical, Ranfac Corporation, HAKKO CO., LTD, and Merit Medical Systems among others.

Aspiration & Biopsy Needles Market: Segments Covered

By Product Type

• Biopsy Needles
  • CNB Needles
  • VAB Needles
• Aspiration Needles

By Application

• Tumor/ Cancer Application
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Bone & Bone Marrow Cancer
  • Other Cancer
• Wound Application
• Other Application

By Procedure

• Image-guided Procedures
• Ultrasound-guided Procedures
• Stereotactic Procedures
• CT-guided Procedures
• MRI-guided Procedures
• Other Image-guided Procedures
• Nonimage-guided Procedures

By End User

• Hospitals & Surgical Centers
• Diagnostic Clinics & Pathology Laboratories
• Ambulatory Care Centers
• Research & Academic Institutes

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10240/

Aspiration & Biopsy Needles Market: Recent Developments

• December 2021: Olympus launched the FDA 510(k)- cleared BF-UC190F endobronchial ultrasound (EBUS) bronchoscope.
• January 2021: Hologic Inc. acquired Somatex Medical Technologies, Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care.
• May 2019: Argon Medical acquired Mana tech Ltd., its exclusive distributor for the UK and Ireland.

New York, June 2022: According to a new research study by Global Insight Services (GIS), the anatomic pathology market is expected to grow rapidly over the next 10 years to reach a value of more than the US $36.5 billion by 2031.

Anatomical pathology is the branch of medicine that comprises the study of body organs and tissues. Anatomical pathology is considered one of the diagnostic branches of medicine, coupled with radiology and other pathology specialties (such as microbiology and chemical pathology). Its roles comprise determining the cause of certain diseases and the effect that they are having on the body, assisting with the choice of treatment that will be given, aiding in giving a prognosis, and determining what may have caused a person’s death.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10238/

Anatomic Pathology Market: Key Drivers

Rising incidence of cancer and other target diseases

Cancer is a leading cause of death across the globe, which accounts for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancer are breast, lung, colon and rectum, and prostate cancers. Around one-third of cancer deaths are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Like HPV and hepatitis, cancer-causing infections are responsible for approximately 30% of cancer cases in low and lower-middle-income countries. Many cancers can be cured if detected early and treated effectively.

The increasing number of clinical trials pertaining to cancer drugs

Anatomic pathology products and services are used in oncology drug trials to analyze quantitative information as well as to detect morphological structures, detect pharmacodynamic markers, and understand drug mechanisms. It is also used to stratify trial subjects based on the responses given by tissues to the drugs. Tissue diagnostics thus facilitate efficient trials and retrospective studies by reducing the cost and time involved in these processes. For instance, in a Phase III study for Roche’s cancer immunotherapy—TECENTRIQ (atezolizumab)—the PD-L1 (programmed death-ligand 1) expression was evaluated using an investigational immunohistochemistry (IHC) test, which was developed by Roche Tissue Diagnostics.

Report Findings

The services segment is likely to hold a major market share during the forecast period

The key factors boosting market growth are the rising geriatric population coupled with increasing incidences of cancer and other chronic diseases.

The disease diagnostics segment is likely to hold a major market share during the forecast period

The key factors propelling the market growth are the increasing incidence of cancer and other diseases coupled with growing geriatric populations

The hospital laboratories are likely to hold a majority of the market share during the forecast period

The market growth of the segment is attributed to the increasing number of patient visits to hospitals, increasing number of in-house diagnostic procedures performed in hospitals, increasing awareness regarding early disease diagnosis, and the availability of reimbursement in the developed market for clinical tests performed in hospitals.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10238/

Competitive Landscape

The key players in the global anatomic pathology market are F. Hoffmann-La Roche AG, Danaher Corporation, PHC Holdings Corporation, Beckton, Dickson and Company, Abcam plc., Hologic, Inc., Agilent Technologies, Merck KGaA, Sakura Finetek, Bio SB, BioGenex, Milestone Medical, Histo-Line Laboratories, Diapath S.p.A, SLEE medical GmbH, Amos Scientific Pty Ltd, MEDITE Medical GmbH, Cell Signaling Technology, Inc., CellPath Ltd., Jinhua Yidi Medical Equipment Co., Ltd., MICROS AUSTRIA, R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED, Lupetec, Medimeas, and Bright Instruments among others.

Anatomic Pathology Market: Segments Covered

By Products & Services

• Services
  • Histopathology
  • Cytopathology
• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Other Consumables
• Instruments
  • Slide Staining Systems
  • Tissue Processing Systems
  • Cells Processors
  • Microtomes
  • Embedding Systems
  • Coverslippers
  • Other Instruments

By Application

• Disease Diagnostics
  • Cancer
  • Other Disease
• Medical Research

By End User

• Hospital Laboratories
• Clinical Laboratories
• Other

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10238/

Anatomic Pathology Market: Recent Developments

• May 2021: Hologic received FDA approval for ThinPrep Genesis processor. The new instrument streamlines these workflows with advanced automation capabilities comprising a chain of custody verification, which prevents misidentification and allows for more confidence in results.
• June 2019: PHC Holdings announced the completion of its acquisition of the Anatomical Pathology business of Thermo Fisher Scientific Inc.

New York, April 2022: According to a new research study by Global Insight Services (GIS), the market amniotic products market is expected to grow rapidly over the next 10 years to reach a value of more than the US $720 million by 2031.

Amniotic fluid is the protective liquid enclosed by the amniotic membrane that serves as a cushion for the growing fetus and facilitates the exchange of nutrients, water, and biochemical products between mother and fetus. Amniotic-derived products, comprising amniotic membrane and amniotic fluid products, are one subtype of orthobiologic that is being considered as a potential treatment option through augmentation of joint inflammation and healing. Amniotic membranes (AM) were initially employed for the treatment of skin disorders such as burns, ulcers, and wounds. The presence of a wide range of products of amniotic products used in the treatment of diseases is sustaining the need of healthcare facilities.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10237/

Amniotic Products Market: Key Drivers

Growing incidence of burn injuries

The high incidence of the burn wound is likely to boost the growth of the market during the forecast period. According to WHO, an estimated 180,000 deaths every year are caused by burns-the high majority occur in low and middle-income economies. In India, over 1,000,000 people are moderately or severely burnt per year. Nearly 173,000 Bangladeshi children are moderately or severely burnt every year. Also, in Bangladesh, Colombia, Egypt, and Pakistan, 17% of children with burns have a temporary disability and 18% have a permanent disability.

Implementation of the 21st Century Cures Act (US)

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation. The Act includes various provisions that may impact the development and approval of several products in the upcoming years. Under this Act, a new “Regenerative Medicine Advanced Therapy” designation has been established, along with a fast-track approval pathway for new regenerative medicine products and therapies. The implementation of this Act can potentially result in the approval of new regenerative medicine products and therapies in the US, as well as stimulate R&D activities in the field of regenerative medicine.

Report Findings

The amniotic membrane segment is likely to dominate the market at a CAGR of XX% during the forecast period.

The key factors such as more effectiveness with compare to amniotic suspension is likely to propel the market growth.

The wound care segment is likely to dominate the market at a constant rate of XX% during the projection period.

The key factors such as the growing incidence of ulcers, traumatic and surgical wounds, and burns and the need for advanced technologies for the treatment is likely to boost the growth of the market.

The hospitals segment is likely to dominate the market at a CAGR of XX% during the forecast period.

The key factors such as the use of amniotic products for ocular use or for using them in tendon and ligament repair are mostly procured in the hospitals coupled with reimbursement policies of this product is easily attained in hospitals are propelling the growth of the market.

Have a question for our analyst: https://www.globalinsightservices.com/inquiry-before-buying/GIS10237/

Competitive Landscape

The key players in the global amniotic products market is MiMedx, Smith & Nephew, Organogenesis Inc., Integra LifeSciences, Stryker, Applied Biologics, Celularity, Inc., Katena Products, Inc., Lucina BioSciences, Next Biosciences, Skye Biologics Holdings, LLC, Surgenex, TissueTech, Inc., Ventris Medical, LLC, StimLabs LLC, VIVEX Biologics, Inc., LifeCell International Pvt. Ltd., NuVision Biotherapies Ltd., Genesis Biologics, Surgilogix, Tides Medical, Orthofix Medical Inc., AlloSource, Merakris Therapeutics, and MTF Biologics among others.

Amniotic Products Market: Segments Covered

By Type

• Amniotic Membranes
  • Cryopreserved Amniotic Membranes
  • Dehydrated Amniotic Membranes
• Amniotic Suspensions

By Application

• Wound Care
• Orthopedics
• Ophthalmology
• Other

By End User

• Hospitals
• Clinics
• Homecare
• Research Institutes
• Academic and Others

By Regions

• North America
• Europe
• Asia Pacific
• Rest of the World

Request report customization: https://www.globalinsightservices.com/request-customization/GIS10237/

Amniotic Products Market: Recent Developments

• June 2021: Mimedx Group, Inc. announced successfully regulatory approval by the Japanese Ministry of Health, Labour and Welfare to market EPIFIX in Japan.
• May 2021: Smith and Nephew announced new evidence to be presented by the Advanced Wound Management franchise and the recently acquired Osiris Therapeutics, Inc. at the symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring (WHS) conference.
• January 2021: Integra Life Sciences completed the acquisition of ACell, Inc.
• January 2021: Organogenesis Holdings Inc. announced that the U.S. Food and Drug Administration (FDA) has granted ReNU, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis (OA), RMAT designation.